{
    "organizations": [],
    "uuid": "d9301bff02c566c857741faa46136a3dcb97c63f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-curetis-cash-and-cash-equivalents/brief-curetis-cash-and-cash-equivalents-at-end-dec-eur-16-3-million-idUSASO00040P",
    "ord_in_thread": 0,
    "title": "BRIEF-Curetis: Cash And Cash Equivalents At End-Dec. EUR 16.3 Million",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 30 (Reuters) - CURETIS NV:\n* CURETIS PUBLISHES FULL-YEAR 2017 FINANCIAL RESULTS AND UPDATED GUIDANCE FOR 2018\n* RECEIVED U.S. FDA CLEARANCE FOR UNYVERO SYSTEM AND UNYVERO LRT CARTRIDGE; COMMERCIAL U.S. ROLL-OUT INITIATED\n* FY REVENUES: EUR 1.2 MILLION (EUR 1.3 MILLION IN 2016) * OPERATING LOSS IN 2017 TOTALED EUR -18.6 MILLION, COMPARED WITH EUR -15.2 MILLION IN 2016\n* FY NET LOSS: EUR -19.3 MILLION (EUR -15.2 MILLION IN 2016)\n* CASH AND CASH EQUIVALENTS AT END DEC EUR 16.3 MILLION VERSUS EUR 22.8MLN YEAR AGO\n* UNYVERO SYSTEM AND UNYVERO LRT APPLICATION CARTRIDGE COMMERCIAL LAUNCH IN U.S. IN Q2-2018\n* SALES OF LRT APPLICATION CARTRIDGE ARE ANTICIPATED TO RAMP UP BY END OF 2018\n* EXPECTS TO EXPERIENCE POSITIVE REVENUE EFFECTS TOWARDS END OF 2018 AND GOING FORWARD.\n* EXPECTS TO INITIATE SITES FOR PROSPECTIVE PATIENT SAMPLE ENROLLMENT INTO ITS SECOND U.S. FDA CLINICAL TRIAL FOR UNYVERO IJI INVASIVE JOINT INFECTION APPLICATION CARTRIDGE BEGINNING IN H2-2018\n* EXPECTS TO COMPLETE UNYVERO IJI INVASIVE JOINT INFECTION APPLICATION CARTRIDGE TRIAL IN 2019\n* AIMS TO INITIATE PROSPECTIVE CLINICAL TRIALS IN CHINA IN SECOND HALF OF 2018.\n* OBJECTIVE IS TO COMPLETE FIRST TRIALS IN 2019, WITH SUBSEQUENT CFDA SUBMISSION AND APPROVALS\n* EXPECTS TO RECEIVE CE-IVD MARKING FOR UNYVERO A30 RQ ANALYZER AS WELL AS FIRST A30 RQ APPLICATION CARTRIDGES DURING COURSE OF 2019.\n* EXPECTS FIRST RESULTS AND INITIAL PRODUCT LAUNCHES FROM MEMORANDUM OF UNDERSTANDING (MOU) SIGNED WITH MGI (A BGI GROUP COMPANY, CHINA) IN 2018 AND 2019 TIMEFRAME\n* AIMS TO AT LEAST DOUBLE ITS REVENUE YEAR-OVER-YEAR IN 2018.\n* EXPECTS NET CASH-BURN FROM OPERATING AND INVESTMENT ACTIVITIES FOR 2018 TO BE AROUND 30 MILLION EUR\n* ALSO EXPECTS TO FURTHER GROW ITS EMPLOYEE BASE AT ITS VARIOUS INTERNATIONAL SITES AND OPERATIONS IN COMING YEARS. Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-30T13:16:00.000+03:00",
    "crawled": "2018-05-01T20:18:58.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "curetis",
        "nv",
        "curetis",
        "publishes",
        "financial",
        "result",
        "updated",
        "guidance",
        "received",
        "fda",
        "clearance",
        "unyvero",
        "system",
        "unyvero",
        "lrt",
        "cartridge",
        "commercial",
        "initiated",
        "fy",
        "revenue",
        "eur",
        "million",
        "eur",
        "million",
        "operating",
        "loss",
        "totaled",
        "eur",
        "million",
        "compared",
        "eur",
        "million",
        "fy",
        "net",
        "loss",
        "eur",
        "million",
        "eur",
        "million",
        "cash",
        "cash",
        "equivalent",
        "end",
        "dec",
        "eur",
        "million",
        "versus",
        "eur",
        "year",
        "ago",
        "unyvero",
        "system",
        "unyvero",
        "lrt",
        "application",
        "cartridge",
        "commercial",
        "launch",
        "sale",
        "lrt",
        "application",
        "cartridge",
        "anticipated",
        "ramp",
        "end",
        "expects",
        "experience",
        "positive",
        "revenue",
        "effect",
        "towards",
        "end",
        "going",
        "forward",
        "expects",
        "initiate",
        "site",
        "prospective",
        "patient",
        "sample",
        "enrollment",
        "second",
        "fda",
        "clinical",
        "trial",
        "unyvero",
        "iji",
        "invasive",
        "joint",
        "infection",
        "application",
        "cartridge",
        "beginning",
        "expects",
        "complete",
        "unyvero",
        "iji",
        "invasive",
        "joint",
        "infection",
        "application",
        "cartridge",
        "trial",
        "aim",
        "initiate",
        "prospective",
        "clinical",
        "trial",
        "china",
        "second",
        "half",
        "objective",
        "complete",
        "first",
        "trial",
        "subsequent",
        "cfda",
        "submission",
        "approval",
        "expects",
        "receive",
        "marking",
        "unyvero",
        "a30",
        "rq",
        "analyzer",
        "well",
        "first",
        "a30",
        "rq",
        "application",
        "cartridge",
        "course",
        "expects",
        "first",
        "result",
        "initial",
        "product",
        "launch",
        "memorandum",
        "understanding",
        "mou",
        "signed",
        "mgi",
        "bgi",
        "group",
        "company",
        "china",
        "timeframe",
        "aim",
        "least",
        "double",
        "revenue",
        "expects",
        "net",
        "operating",
        "investment",
        "activity",
        "around",
        "million",
        "eur",
        "also",
        "expects",
        "grow",
        "employee",
        "base",
        "various",
        "international",
        "site",
        "operation",
        "coming",
        "year",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}